Publications by authors named "David Hokey"

Claim this Profile
S
Safety and Immunogenicity of the H56:IC31 Tuberculosis Vaccine Candidate in Adults Successfully Treated for Drug-Susceptible Pulmonary Tuberculosis: A Phase 1 Randomized Trial.
Dereck Tait, Andreas Diacon, Álvaro H Borges, Elana van Brakel, David Hokey

J Infect Dis· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A 2-Dose AERAS-402 Regimen Boosts CD8 Polyfunctionality in HIV-Negative, BCG-Vaccinated Recipients.
Dhanasekaran Sivakumaran, Gretta Blatner, Rasmus Bakken, David Hokey, Christian Ritz

Front Immunol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multidimensional analyses reveal modulation of adaptive and innate immune subsets by tuberculosis vaccines.
Virginie Rozot, Elisa Nemes, Hennie Geldenhuys, Munyaradzi Musvosvi, Asma Toefy, David A Hokey

Commun Biol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to animals: an updated review.
Sina Salajegheh Tazerji, Phelipe Magalhães Duarte, Parastoo Rahimi, Fatemeh Shahabinejad, Santosh Dhakal, David A Hokey

J Transl Med· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD4+ T cell cytokine responses to the DAR-901 booster vaccine in BCG-primed adults: A randomized, placebo-controlled trial.
Tereza Masonou, David A Hokey, Timothy Lahey, Alice Halliday, Luis C Berrocal-Almanza

PLoS One· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial.
Sara Suliman, Angelique Kany Kany Luabeya, Hennie Geldenhuys, Michele Tameris, Soren T Hoff, David Hokey

Am J Respir Crit Care Med· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial.
Rhea N Coler, Tracey A Day, Ruth Ellis, Franco M Piazza, Anna Marie Beckmann, David Hokey

NPJ Vaccines· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination.
Elisa Nemes, Hennie Geldenhuys, Virginie Rozot, Kathryn T Rutkowski, Frances Ratangee, David A Hokey

N Engl J Med· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: A randomized, controlled trial of DAR-901.
C Fordham von Reyn, Timothy Lahey, Robert D Arbeit, Bernard Landry, Leway Kailani, David A Hokey

PLoS One· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Cross-Species Mycobacterial Growth Inhibition Assay (MGIA) Project, 2010-2014.
Michael J Brennan, Rachel Tanner, Sheldon Morris, Thomas J Scriba, Jacqueline M Achkar, David A Hokey

Clin Vaccine Immunol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Immunogenicity of Adenovirus 35 Tuberculosis Vaccine Candidate in Adults with Active or Previous Tuberculosis. A Randomized Trial.
Richard N van Zyl-Smit, Aliasgar Esmail, Mary E Bateman, Rodney Dawson, Jonathan Goldin, David A Hokey

Am J Respir Crit Care Med· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials.
Maria Norrby, Timo Vesikari, Lars Lindqvist, Markus Maeurer, Raija Ahmed, David A Hokey

Vaccine· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adenovirally-Induced Polyfunctional T Cells Do Not Necessarily Recognize the Infected Target: Lessons from a Phase I Trial of the AERAS-402 Vaccine.
Melissa Nyendak, Gwendolyn M Swarbrick, Amanda Duncan, Meghan Cansler, Ervina Winata Huff, David Hokey

Sci Rep· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A new tool for tuberculosis vaccine screening: Ex vivo Mycobacterial Growth Inhibition Assay indicates BCG-mediated protection in a murine model of tuberculosis.
Andrea Zelmer, Rachel Tanner, Elena Stylianou, Timon Damelang, Sheldon Morris, David A Hokey

BMC Infect Dis· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults.
Sharon Sheehan, Stephanie A Harris, Iman Satti, David A Hokey, Veerabadran Dheenadhayalan

PLoS One· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Immunogenicity of the Recombinant BCG Vaccine AERAS-422 in Healthy BCG-naïve Adults: A Randomized, Active-controlled, First-in-human Phase 1 Trial.
Daniel F Hoft, Azra Blazevic, Asmir Selimovic, Aldin Turan, Jan Tennant, David A Hokey

EBioMedicine· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The frequencies of IFNγ+IL2+TNFα+ PPD-specific CD4+CD45RO+ T-cells correlate with the magnitude of the QuantiFERON® gold in-tube response in a prospective study of healthy indian adolescents.
Synne Jenum, Harleen M S Grewal, David A Hokey, John Kenneth, Mario Vaz

PLoS One· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A nonhuman primate toxicology and immunogenicity study evaluating aerosol delivery of AERAS-402/Ad35 vaccine: Evidence for transient t cell responses in peripheral blood and robust sustained responses in the lungs.
David A Hokey, Robert Wachholder, Patricia A Darrah, Diane L Bolton, Dan H Barouch

Hum Vaccin Immunother· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial.
Hennie Geldenhuys, Helen Mearns, David J C Miles, Michele Tameris, David Hokey

Vaccine· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4(+) T cell counts >350 cells/mm(3).
Gavin John Churchyard, Margaret Ann Snowden, David Hokey, Veerabadran Dheenadhayalan, J Bruce McClain

Vaccine· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mycobacterium tuberculosis Erdman infection of rhesus macaques of Chinese origin.
Jing Zhang, Qiaoyang Xian, Ming Guo, Zhixiang Huang, Yan Rao, David Hokey

Tuberculosis (Edinb)· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human.
Jaap T van Dissel, Simone A Joosten, Søren T Hoff, Darius Soonawala, Corine Prins, David A Hokey

Vaccine· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responses.
Benjamin M N Kagina, Michele D Tameris, Hennie Geldenhuys, Mark Hatherill, Brian Abel, David A Hokey

Vaccine· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aerosol vaccination with AERAS-402 elicits robust cellular immune responses in the lungs of rhesus macaques but fails to protect against high-dose Mycobacterium tuberculosis challenge.
Patricia A Darrah, Diane L Bolton, Andrew A Lackner, Deepak Kaushal, Pyone Pyone Aye, David A Hokey

J Immunol· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TB Vaccines: The (Human) Challenge Ahead.
David A Hokey

Mycobact Dis· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis